{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:15:41Z","timestamp":1770747341915,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T00:00:00Z","timestamp":1335225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2369-13-20","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T00:01:16Z","timestamp":1335312076000},"source":"Crossref","is-referenced-by-count":38,"title":["Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort"],"prefix":"10.1186","volume":"13","author":[{"name":"MASTERPLAN group study","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc G","family":"Vervloet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan D","family":"van Zuilen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke C","family":"Heijboer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet M","family":"ter Wee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel L","family":"Bots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J","family":"Blankestijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack FM","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,24]]},"reference":[{"key":"272_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004, 351: 1296-1305. 10.1056\/NEJMoa041031.","journal-title":"N Engl J Med"},{"key":"272_CR2","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/bmj.38814.566019.2F","volume":"332","author":"M Tonelli","year":"2006","unstructured":"Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006, 332: 1426-10.1136\/bmj.38814.566019.2F.","journal-title":"BMJ"},{"key":"272_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008, 359: 584-592. 10.1056\/NEJMoa0706130.","journal-title":"N Engl J Med"},{"key":"272_CR4","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1681\/ASN.2010121224","volume":"22","author":"J Kendrick","year":"2011","unstructured":"Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M: FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis. J Am Soc Nephrol. 2011, 22: 1913-1922. 10.1681\/ASN.2010121224.","journal-title":"J Am Soc Nephrol"},{"key":"272_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2215\/CJN.04250510","volume":"6","author":"SM Titan","year":"2011","unstructured":"Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, Moyses RM: FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol. 2011, 6: 241-247. 10.2215\/CJN.04250510.","journal-title":"Clin J Am Soc Nephrol"},{"key":"272_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/ndt\/gfp699","volume":"25","author":"JH Ix","year":"2010","unstructured":"Ix JH, Shlipak MG, Wassel CL, Whooley MA: Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010, 25: 993-997. 10.1093\/ndt\/gfp699.","journal-title":"Nephrol Dial Transplant"},{"key":"272_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/ki.2010.194","volume":"78","author":"MI Yilmaz","year":"2010","unstructured":"Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C: FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010, 78: 679-685. 10.1038\/ki.2010.194.","journal-title":"Kidney Int"},{"key":"272_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","volume":"205","author":"MA Mirza","year":"2009","unstructured":"Mirza MA, Larsson A, Lind L, Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009, 205: 385-390. 10.1016\/j.atherosclerosis.2009.01.001.","journal-title":"Atherosclerosis"},{"key":"272_CR9","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, guillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John , Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe O, Kuro O, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011, 121: 4393-4408. 10.1172\/JCI46122.","journal-title":"J Clin Invest"},{"key":"272_CR10","first-page":"30","volume":"18","author":"AD Van Zuilen","year":"2005","unstructured":"Van Zuilen AD, Wetzels JF, Blankestijn PJ, Bots ML, Van Buren M, Ten Dam MA, Kaasjager KA, Van De V, Vleming LJ, Ligtenberg G, Ligtenberg G: Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. J Nephrol. 2005, 18: 30-34.","journal-title":"J Nephrol"},{"key":"272_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1258\/acb.2009.009066","volume":"46","author":"AC Heijboer","year":"2009","unstructured":"Heijboer AC, Levitus M, Vervloet MG, Lips P, ter Wee PM, Dijstelbloem HM, Blankenstein MA: Determination of fibroblast growth factor 23. Ann Clin Biochem. 2009, 46: 338-340. 10.1258\/acb.2009.009066.","journal-title":"Ann Clin Biochem"},{"key":"272_CR12","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/qjmed\/hcl108","volume":"99","author":"PJ Twomey","year":"2006","unstructured":"Twomey PJ, Reynolds TM: The MDRD formula and validation. QJM. 2006, 99: 804-805. 10.1093\/qjmed\/hcl108.","journal-title":"QJM"},{"key":"272_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2169\/internalmedicine.47.0730","volume":"47","author":"S Fukumoto","year":"2008","unstructured":"Fukumoto S: Physiological regulation and disorders of phosphate metabolism-pivotal role of fibroblast growth factor 23. Intern Med. 2008, 47: 337-343. 10.2169\/internalmedicine.47.0730.","journal-title":"Intern Med"},{"key":"272_CR14","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/ki.2011.27","volume":"79","author":"H Juppner","year":"2011","unstructured":"Juppner H: Phosphate and FGF-23. Kidney Int Suppl. 2011, 79: S24-S27.","journal-title":"Kidney Int Suppl"},{"key":"272_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2215\/CJN.04730510","volume":"6","author":"MG Vervloet","year":"2011","unstructured":"Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM: Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol. 2011, 6: 383-389. 10.2215\/CJN.04730510.","journal-title":"Clin J Am Soc Nephrol"},{"key":"272_CR16","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T: PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010, 299: F882-F889. 10.1152\/ajprenal.00360.2010.","journal-title":"Am J Physiol Renal Physiol"},{"key":"272_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00223-010-9426-4","volume":"88","author":"H Hapidin","year":"2011","unstructured":"Hapidin H, Othman F, Soelaiman IN, Shuid AN, Mohamed N: Effects of nicotine administration and nicotine cessation on bone histomorphometry and bone biomarkers in Sprague-Dawley male rats. Calcif Tissue Int. 2011, 88: 41-47. 10.1007\/s00223-010-9426-4.","journal-title":"Calcif Tissue Int"},{"key":"272_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00198-010-1238-x","volume":"22","author":"J Tamaki","year":"2011","unstructured":"Tamaki J, Iki M, Fujita Y, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N: Impact of smoking on bone mineral density and bone metabolism in elderly men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int. 2011, 22: 133-141. 10.1007\/s00198-010-1238-x.","journal-title":"Osteoporos Int"},{"key":"272_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006, 444: 770-774. 10.1038\/nature05315.","journal-title":"Nature"},{"key":"272_CR20","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2010121251","volume":"22","author":"MH de Borst","year":"2011","unstructured":"de Borst MH, Vervloet MG, ter Wee PM, Navis G: Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011, 22: 1603-1609. 10.1681\/ASN.2010121251.","journal-title":"J Am Soc Nephrol"},{"key":"272_CR21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.healun.2009.03.003","volume":"28","author":"AK Khanna","year":"2009","unstructured":"Khanna AK, Xu J, Baquet C, Mehra MR: Adverse effects of nicotine and immunosuppression on proximal tubular epithelial cell viability, tissue repair and oxidative stress gene expression. J Heart Lung Transplant. 2009, 28: 612-620. 10.1016\/j.healun.2009.03.003.","journal-title":"J Heart Lung Transplant"},{"key":"272_CR22","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00198-008-0780-2","volume":"20","author":"R Marsell","year":"2009","unstructured":"Marsell R, Mirza MA, Mallmin H, Karlsson M, Mellstrom D, Orwoll E, Ohlsson C, Jonsson KB, Ljunggren O, Larsson TE: Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int. 2009, 20: 1167-1173. 10.1007\/s00198-008-0780-2.","journal-title":"Osteoporos Int"},{"key":"272_CR23","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011, 305: 2432-2439. 10.1001\/jama.2011.826.","journal-title":"JAMA"},{"key":"272_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1530\/EJE-11-0577","volume":"165","author":"M Dalal","year":"2011","unstructured":"Dalal M, Sun K, Cappola AR, Ferrucci L, Crasto C, Fried LP, Semba RD: Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol. 2011, 165: 797-803. 10.1530\/EJE-11-0577.","journal-title":"Eur J Endocrinol"},{"key":"272_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1053\/j.jrn.2010.07.002","volume":"21","author":"T Isakova","year":"2011","unstructured":"Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A: Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr. 2011, 21: 295-302. 10.1053\/j.jrn.2010.07.002.","journal-title":"J Ren Nutr"},{"key":"272_CR26","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2005111185","volume":"17","author":"S Liu","year":"2006","unstructured":"Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006, 17: 1305-1315. 10.1681\/ASN.2005111185.","journal-title":"J Am Soc Nephrol"},{"key":"272_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/0272-6386(95)90165-5","volume":"26","author":"G D'Amico","year":"1995","unstructured":"D'Amico G, Ferrario F, Rastaldi MP: Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. Am J Kidney Dis. 1995, 26: 124-132. 10.1016\/0272-6386(95)90165-5.","journal-title":"Am J Kidney Dis"},{"key":"272_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med. 1998, 339: 1448-1456. 10.1056\/NEJM199811123392007.","journal-title":"N Engl J Med"},{"key":"272_CR29","first-page":"119","volume":"57","author":"M Renke","year":"2010","unstructured":"Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Lysiak-Szydlowska W, Wozniak M, Rutkowski B: Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochim Pol. 2010, 57: 119-123.","journal-title":"Acta Biochim Pol"},{"key":"272_CR30","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007, 18: 2600-2608. 10.1681\/ASN.2006080936.","journal-title":"J Am Soc Nephrol"},{"key":"272_CR31","doi-asserted-by":"publisher","first-page":"F1577","DOI":"10.1152\/ajprenal.00463.2006","volume":"293","author":"F Perwad","year":"2007","unstructured":"Perwad F, Zhang MY, Tenenhouse HS, Portale AA: Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007, 293: F1577-F1583. 10.1152\/ajprenal.00463.2006.","journal-title":"Am J Physiol Renal Physiol"},{"key":"272_CR32","first-page":"S3","volume":"8","author":"WB Kannel","year":"1990","unstructured":"Kannel WB, Higgins M: Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens Suppl. 1990, 8: S3-S8.","journal-title":"J Hypertens Suppl"},{"key":"272_CR33","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1111\/j.1523-1755.2004.09201.x","volume":"33","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw D: Albuminuria, not only a cardiovascular\/renal risk marker, but also a target for treatment?. Kidney Int Suppl. 2004, 33: S2-S6.","journal-title":"Kidney Int Suppl"},{"key":"272_CR34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.2215\/CJN.01660309","volume":"4","author":"RN Foley","year":"2009","unstructured":"Foley RN: Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol. 2009, 4: 1136-1139. 10.2215\/CJN.01660309.","journal-title":"Clin J Am Soc Nephrol"},{"key":"272_CR35","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1038\/ki.2011.24","volume":"79","author":"K Hruska","year":"2011","unstructured":"Hruska K, Mathew S, Lund R, Fang Y, Sugatani T: Cardiovascular risk factors in chronic kidney disease: does phosphate qualify?. Kidney Int Suppl. 2011, 79: S9-13.","journal-title":"Kidney Int Suppl"},{"key":"272_CR36","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/ndt\/14.6.1445","volume":"14","author":"LT Pijls","year":"1999","unstructured":"Pijls LT, de Vries H, Donker AJ, van Eijk JT: The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant. 1999, 14: 1445-1453. 10.1093\/ndt\/14.6.1445.","journal-title":"Nephrol Dial Transplant"},{"key":"272_CR37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/jc.2009-1603","volume":"95","author":"T Shimada","year":"2010","unstructured":"Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H: Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010, 95: 578-585. 10.1210\/jc.2009-1603.","journal-title":"J Clin Endocrinol Metab"},{"key":"272_CR38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1373\/clinchem.2005.049742","volume":"51","author":"CP Price","year":"2005","unstructured":"Price CP, Newall RG, Boyd JC: Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem. 2005, 51: 1577-1586. 10.1373\/clinchem.2005.049742.","journal-title":"Clin Chem"},{"key":"272_CR39","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","volume":"26","author":"E Gonzalez-Parra","year":"2011","unstructured":"Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A: Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant. 2011, 26: 2567-2571. 10.1093\/ndt\/gfr144.","journal-title":"Nephrol Dial Transplant"},{"key":"272_CR40","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","volume":"9","author":"F Koiwa","year":"2005","unstructured":"Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T: Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial. 2005, 9: 336-339. 10.1111\/j.1744-9987.2005.00293.x.","journal-title":"Ther Apher Dial"},{"key":"272_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol. 2010, 5: 286-291. 10.2215\/CJN.05420709.","journal-title":"Clin J Am Soc Nephrol"},{"key":"272_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2215\/CJN.03630509","volume":"5","author":"JB Wetmore","year":"2010","unstructured":"Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD: Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol. 2010, 5: 110-116. 10.2215\/CJN.03630509.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-13-20\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T03:40:07Z","timestamp":1548214807000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-13-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,24]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["272"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-13-20","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,24]]},"article-number":"20"}}